ACCL1131, A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT)

Study ID
STU 102013-075

Cancer Related

Healthy Volunteers

Study Sites

Niechelle Loyd

Principal Investigator
Victor Aquino


Participants will receive their planned SCT conditioning regimen that includes high doses of chemotherapy or radiation. Taking part in this study will not change the cancer treatment plan.

Before the SCT conditioning regimen is completed, all eligible and consenting participants will be randomized to receive one of two antifungal drugs:
-- azole antifungal arm [?] Current standard treatment. Participants will receive Fluconazole or Voriconazole by infusion in a vein over 1-2 hours (or longer) or by mouth.
-- Caspofungin arm [?] experimental treatment. Participants will receive Caspofungin by infusion in a vein over 1 hour. The dose on the first day is different from the dose given in the days that follow.

all participants will begin receiving their assigned antifungal drug on the day of the SCT (called Day 0) and until Day 42 or discharge from the hospital.

Participant Eligibility

1. Age: For centers that will use fluconazole as the antifungal comparator:
Age >= 3 months and < 21 years.
For centers that will use voriconazole as the antifungal comparator:
Age >= 2 years and < 21 years.
2. Diagnosis
- - The patient must be undergoing allogeneic HCT from any donor (including matched related) with any stem cell source for any underlying condition.
3. Performance Level
Patients must have a performance status corresponding to ECOG scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients <= 16 years of age.
See under Standard Sections for Protocols.
4. Organ Function Requirements
-- Adequate Renal Function based on Creatinine clearance or radioisotope GFR or A serum creatinine
-- Adequate Liver Function Defined As:
- Total bilirubin < 2.5 mg/dL unless the increase in bilirubin is attributable to Gilbert[?]s Syndrome, and
- SGOT (AST) or SGPT (ALT) < 5X upper limit of normal (ULN) for age.